Arc Institute and Instadeep announce two new models for nucleic acid data (ExoGRU and SegmentNT), a new drug is approved for MASH with an ASO likely to become a second approval, ZephyrAI raises a $111m series A, and hospitals are still wondering how to leverage large language models in their practices.
This week in TechBio 2024/03/18
This week in TechBio 2024/03/18
This week in TechBio 2024/03/18
Arc Institute and Instadeep announce two new models for nucleic acid data (ExoGRU and SegmentNT), a new drug is approved for MASH with an ASO likely to become a second approval, ZephyrAI raises a $111m series A, and hospitals are still wondering how to leverage large language models in their practices.